Susanne Malander
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Susanne Malander has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Mef Nilbert
Institute of Clinical Medicine, Dept. Oncology and Pathology Lund University Sweden
2 shared publications A. Måsbäck
Departments of *Oncology and †Pathology, Lund University Hospital, Lund, Sweden
1 shared publication- Anna Måsbäck
Department of Surgical Pathology, Division of Laboratory Medicine, Skåne University Hospital, Lund, Sweden
1 shared publication Britta Halvarsson
1 shared publicationEva Rambech
1 shared publication- Gabriella Honeth
Division of Oncology, Department of Clinical Sciences, Lund University, Lund, Sweden
1 shared publication
Latest Publications
- Open Access
MET Expression and Cancer Stem Cell Networks Impact Outcome in High-Grade Serous Ovarian Cancer
Overexpression of the receptor tyrosine kinase MET has been linked to poor survival in several cancer types, and MET has been suggested to interact with stem cell networks. In vitro studies have further suggested a possible benefit of a combined treatment using PARP and MET inhibitors. We used a tissue microarray (TMA) with 130 samples of advanced-stage high-grade serous fallopian tube/ovarian cancer (HGSC) to investigate the prognostic value of MET protein expression alone and in combination with the stem cell factor SOX2. The possible synergistic effects of a PARP and MET inhibitor treatment were evaluated in two cell lines with BRCA1 or BRCA2 deficiency and in their BRCA1/2-proficient counterparts. Patients with tumors positive for MET had worse overall survival (log-rank test, p = 0.015) compared to patients with MET-negative tumors. The prognostic role of MET was even more prominent in the subgroup of patients with SOX2-negative tumors (p = 0.0081). No synergistic effects of the combined treatment with PARP and MET inhibitors were found in the cell lines examined. We conclude that MET expression could be used as a marker for OS in HGSC and that stemness should be taken into consideration when evaluating the mechanisms of this effect.
Open AccessMET Expression and Cancer Stem Cell Networks Impact Outcome in High-Grade Serous Ovarian Cancer
Overexpression of the receptor tyrosine kinase MET has been linked to poor survival in several cancer types, and MET has been suggested to interact with stem cell networks. In vitro studies have further suggested a possible benefit of a combined treatment using PARP and MET inhibitors. We used a tissue microarray (TMA) with 130 samples of advanced-stage high-grade serous fallopian tube/ovarian cancer (HGSC) to investigate the prognostic value of MET protein expression alone and in combination with the stem cell factor SOX2. The possible synergistic effects of a PARP and MET inhibitor treatment were evaluated in two cell lines with BRCA1 or BRCA2 deficiency and in their BRCA1/2-proficient counterparts. Patients with tumors positive for MET had worse overall survival (log-rank test, p = 0.015) compared to patients with MET-negative tumors. The prognostic role of MET was even more prominent in the subgroup of patients with SOX2-negative tumors (p = 0.0081). No synergistic effects of the combined treatment with PARP and MET inhibitors were found in the cell lines examined. We conclude that MET expression could be used as a marker for OS in HGSC and that stemness should be taken into consideration when evaluating the mechanisms of this effect.
- 1 July 2007
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 17 (4) , 789-793
Ovarian cancer at young age: the contribution of mismatch-repair defects in a population-based series of epithelial ovarian cancer before age 40
- 1 July 2007
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 17 (4) , 789-793
Ovarian cancer at young age: the contribution of mismatch-repair defects in a population-based series of epithelial ovarian cancer before age 40
- 1 May 2006
- Published by Elsevier in Gynecologic Oncology
- Vol. 101 (2) , 238-243
The contribution of the hereditary nonpolyposis colorectal cancer syndrome to the development of ovarian cancer
- 1 May 2006
- Published by Elsevier in Gynecologic Oncology
- Vol. 101 (2) , 238-243
The contribution of the hereditary nonpolyposis colorectal cancer syndrome to the development of ovarian cancer